地址: 上海市宜山路 號A座 電話: 傳真: 網址: 郵編: ( ) 持 續 創 新 樂 享 健 康 2024年 環境﹑社會及管治（ESG）暨可持續發展報告 上海復星醫藥(集團)股份有限公司 2024年環境﹑社會及管治（ESG）暨可持續發展報告 上海復星醫藥 集團 股份有限公司 | 目錄 | 01 | | --- | --- | | 董事長致辭 | 02 | | 關於本報告 | 04 | | 關於復星醫藥 | 06 | | 2024年公司大事記 | 07 | | 聯合國可持續發展目標（SDGs）目錄 | 09 | | 企業管治 | | | --- | --- | | 1.1 企業管治 | 11 | | 1.2 風險管控 | 22 | | 1.3 商業道德 | 24 | | 1.4 信息安全與 隱私保護 | 35 | 合作共贏 4 | 4.1 供應商管理 | 98 | | --- | --- | | 4.2 可持續供應鏈 | 103 | | 4.3 協會成員資格 | 106 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 1289 (86 21) 3398 7 ...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 (a joint stock limited company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stock Code 股份代號：02196） NOTIFICATION LETTER 通知信函 23 April 2025 Should you have any queries relating to this notification, please call the H Share Registrar's telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays). By Order of the B ...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 (a joint stock limited company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stock Code 股份代號：02196） It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Repl ...

Financial Performance - Total revenue for 2024 was RMB 40,910 million, a slight decrease from RMB 41,249 million in 2023[9] - Operating profit increased significantly to RMB 2,780 million, compared to RMB 1,100 million in the previous year[9] - The net profit attributable to shareholders rose to RMB 2,770 million, up from RMB 2,399 million in 2023, reflecting a growth of 15.5%[9] - The gross profit margin improved to 47.77%, compared to 47.64% in the previous year[9] - The company achieved a revenue of RMB 40,910 million during the reporting period, representing a year-on-year decrease of 0.82%[25] - The net profit attributable to shareholders increased by 15.46% year-on-year to RMB 2,770 million, with earnings per share rising to RMB 1.04, up 15.56%[32] - The pharmaceutical business generated revenue of RMB 28,776 million, down 4.34% year-on-year, while the segment profit increased by 64.64% to RMB 3,250 million[25] - The medical health services business achieved revenue of RMB 7,642 million, a year-on-year increase of 14.62%, with segment performance improving by RMB 272 million[144] Research and Development - Research and development expenses totaled RMB 5,554 million, with RMB 3,644 million classified as R&D costs, reflecting a focus on enhancing the R&D pipeline[29] - The company has developed and approved 16 innovative drugs/biosimilars during the reporting period, including new indications for Sruvli monoclonal injection and 4 new indications for Adalimumab injection in China[14] - The company is focusing on enhancing self-research capabilities while integrating global innovative technologies through licensing and industrial funds[21] - The company has initiated 18 clinical trial projects for innovative drugs/biosimilars during the reporting period[59] - The company has established a Scientific Advisory Board to enhance innovation strategy and improve R&D efficiency, focusing on core therapeutic areas such as oncology and immunology[103] - The company has made significant progress in its R&D pipeline, with 7 innovative drugs/biosimilars approved for 16 indications and 18 clinical trial approvals during the reporting period[103] Market Expansion and Internationalization - The overseas business proportion continued to increase, reflecting the company's efforts in international market expansion[13] - The company has established a global commercial team of over 1,000 people for pharmaceutical and medical device businesses in overseas markets, enhancing digital management and user operation capabilities[18] - The company has expanded its sales network to over 40 countries in Africa and is building a local manufacturing project in Côte d'Ivoire[16] - The company has launched new direct sales channels in Thailand and is enhancing its registration and commercialization capabilities in Southeast Asia[60] - The company is actively pursuing international market expansion through partnerships and collaborations with global institutions to capture early-stage innovative products[200] Product Development and Innovation - The company is committed to upgrading its production and manufacturing systems, including the establishment of new production bases for formulations and APIs[21] - The company has launched 33 generic products in the U.S. market and is preparing for the commercialization of Sruvli monoclonal injection[15] - The company has eight innovative drugs/biosimilars in the pre-approval or key clinical stages, including the MEK1/2 selective inhibitor FCN-159, which has two indications accepted for priority review[56] - The company is focusing on core therapeutic areas and optimizing its business structure to support innovative product development[83] - The company is pursuing a differentiated development strategy with its anti-PD-1 monoclonal antibody, actively conducting multiple clinical trials globally for various cancers[96] Operational Efficiency and Cost Management - The company is focusing on integrating R&D, production, and marketing to enhance operational efficiency[13] - The company has optimized its asset structure, accelerating cash flow with a total of nearly RMB 3,000 million returned since 2024[20] - Continuous improvement in lean management has been emphasized, focusing on quality enhancement, cost control, and efficiency improvement[73] - The company is actively integrating supply chains and improving operational efficiency in the medical diagnostics business, further enhancing productivity[143] Strategic Partnerships and Collaborations - The company has established a strategic partnership with Abbott, granting commercialization rights for 5 self-developed products across 69 countries in Asia, Latin America, and the Caribbean[64] - The company has signed a strategic cooperation agreement with Sermonix to develop and commercialize at least two indications for lasofoxifene in China and the Greater China region[65] - The company has increased its stake in the cell therapy platform Fosun Kite to 100% and is advancing collaboration with Kite Pharma in the CAR-T cell therapy field, focusing on Axi-Cel and Brexu-Cel in China, Hong Kong, and Macau[97] Financial Health and Debt Management - The company’s debt-to-asset ratio improved to 48.99%, down from 50.12% in the previous year[9] - The company's total debt as of December 31, 2024, was RMB 33,064 million, an increase from RMB 32,574 million in 2023, with a debt-to-asset ratio of 28.16%[36] - The company has unused bank credit facilities totaling RMB 22,271 million, with a total credit line of approximately RMB 55,866 million available[39] Digital Transformation and AI Integration - The company continues to deepen its digital transformation and AI applications in drug development and smart healthcare[19] - The PharmAID decision intelligence platform has been implemented, achieving a data update efficiency of T+1, enhancing decision-making in drug development[71] - The company is committed to digital transformation and AI upgrades to improve operational efficiency and production processes[198] Regulatory Approvals and Compliance - The company’s production facilities have passed FDA inspections with zero defects, reinforcing the foundation for international market entry[67] - The company is committed to responsible marketing and compliance training for employees, enhancing awareness of compliance in marketing practices[70] - The company has received approval for Trastuzumab injection in the US and Canada, and the application for the listing of Sruvelizumab injection is under positive review by the European Medicines Agency, expected to be approved in February 2025[61]

Transaction Overview - The company plans to acquire a total of 21,034,313 non-listed shares of Fuhong Hanlin at a price of HKD 24.60 per share, representing approximately 3.87% of the total shares outstanding as of the announcement date [2][7] - The total transaction value amounts to HKD 517,444,099.80, which is equivalent to approximately RMB [2][7] - Following the completion of this acquisition, the company's ownership in Fuhong Hanlin will increase from 59.56% to 63.43% [3][9] Related Party Transactions - The acquisition includes a related party transaction as the company’s executive director, Ms. Guan Xiaohui, is also a director of Wuxi Tongshan, which is a related party [3][9] - The shares acquired from Wuxi Tongshan amount to 4,666,667, constituting part of the related party transaction [3][9] Regulatory Compliance - The acquisition does not constitute a major asset restructuring as defined by the relevant regulations [4][10] - No approval from the board of directors or shareholders is required for this transaction [5][11] Company Background - Fuhong Hanlin, established in February 2010 and listed on the Hong Kong Stock Exchange in September 2019, focuses on the research, production, and sales of monoclonal antibody drugs [12] - As of the announcement date, Fuhong Hanlin has a total of 543,494,853 shares, including 163,428,541 H-shares and 380,066,312 non-listed shares [12] Financial Performance - As of December 31, 2024, Fuhong Hanlin reported total assets of RMB 1,059,752,000, equity attributable to shareholders of RMB 301,362,000, and total liabilities of RMB 758,390,000 [13] - For the year 2024, Fuhong Hanlin achieved revenue of RMB 572,445,000 and a net profit of RMB 82,047,000 [13] Seller Information - Wuxi Tongshan, one of the sellers, was established in May 2016 and has total assets of RMB 9,519,000 as of December 31, 2024 [14] - Other sellers include Shanghai Shanwu, Zhoushan Guoyun, and Henlink, each with varying business focuses and financial standings [15][16][17] Impact on the Company - The acquisition reflects the company's confidence in Fuhong Hanlin's growth and value, enhancing its stake in a key antibody technology platform [19]

由于复星医药公司执行董事关晓晖女士兼任无锡通善间接控股股东HermedCapital的董事，本次交易也 构成关联交易。 2024年6月24日，复星医药抛出了一则关于拟以不超过约54.07亿港元私有化复宏汉霖计划。不过，在今 年1月复宏汉霖股票大会投票中，该计划未能获得通过，导致私有化方案搁浅。 今年以来，复宏汉霖二级市场上的股价涨幅超过40%，股价表现抢眼背后，也跟该公司业绩连续实现盈 利有关。 2024年，复宏汉霖实现营业收入约57.24亿元，净利润约8.21亿元，已连续两年通过产品销售实现盈利。 在国内市场竞争激烈的背景下，拓展海外市场是很多创新药企追逐的梦想，复宏汉霖正试图在海外市场 大展拳脚。 复星医药持有复宏汉霖的股权比例将增至63.43%。 复星医药（600196.SH、02196.HK）私有化复宏汉霖（02696.HK）计划没有成行后，拟改为增持后者股 份。 4月21日晚间，复星医药发布公告称，基于对复宏汉霖发展的信心及价值的认可，2025年4月11日至4月 17日期间，控股子公司复星医药产业与上海善梧、无锡通善、舟山果运及Henlink分别达成转让协议， 拟以港币24.60元/股的价格受让该等 ...

Mergers and Acquisitions - Fosun Pharma's subsidiary plans to acquire 21,034,300 non-listed shares of Fuhong Hanlin at HKD 24.60 per share, totaling HKD 517 million, increasing its stake to 63.43% [1] - Xinle Energy's wholly-owned subsidiary intends to purchase a 3% stake in Beijing Zhouyuan for CNY 2.4 million, aimed at expanding its data center power market [2] - Zhejiang Yongqiang approved the acquisition of stakes in two companies from its subsidiary, involving CNY 19.41 million for a 2.718% stake in Yishang Travel and CNY 97.33 million for 25.0028% of Tengxuan Tourism Group [3] Performance Disclosure - Anji Food reported a revenue of CNY 607 million for 2024, a decrease of 4.06%, while net profit increased by 23.29% to CNY 38.33 million, attributed to slower recovery in the catering industry [4] - Yanjing Beer achieved a revenue of CNY 14.667 billion for 2024, a growth of 3.20%, with net profit rising 63.74% to CNY 1.056 billion, driven by increased sales of its flagship product [5] Share Buybacks - China Communications Construction Company plans to repurchase A-shares worth CNY 500 million to 1 billion, while its controlling shareholder intends to increase H-shares by CNY 250 million to 500 million [6] - Aohai Technology announced a share buyback plan of CNY 40 million to 80 million, targeting a price of up to CNY 59 per share [7] - Vanadium Titanium Co. plans to repurchase shares worth CNY 100 million to 200 million, with a maximum price of CNY 4.30 per share, while its controlling shareholder plans to increase holdings by CNY 50 million to 100 million [9] Stock Risk Warnings - Rock Shares will face delisting risk warnings due to negative net profit and insufficient revenue, with stock trading suspended for one day [11] - Greenland Holdings received an administrative penalty for failing to disclose litigation matters, leading to corrective measures from the Shanghai Securities Regulatory Bureau [12] - Shandong Huapeng reported a negative retained earnings of CNY 900 million and a debt ratio of 97.47%, indicating potential risks to its ongoing operations [13] - Aowei Communication anticipates a net loss of CNY 60 million to 90 million for 2024, which may trigger delisting risk warnings [14]

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（ 集團 ）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 增持控股子公司股權的提示性公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 中國，上海 2025年4月21日 於本公告日期，本公司之執行董事為吳以芳先生、王可心先生、關曉暉女士及文德鏞先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及陳玉卿先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 证券代码：600196 ...

上海复星医药（集团）股份有限公司 关于增持控股子公司股权的提示性公告 证券代码：600196 股票简称：复星医药 编号：临 2025-071 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●交易概况： 基于对复宏汉霖发展的信心及价值的认可，2025年4月11日至4月17日期间， 控股子公司复星医药产业与上海善梧、无锡通善、舟山果运及Henlink分别达成 转让协议，拟以港币24.60元/股的价格受让该等卖方持有的合计21,034,313股复 宏汉霖非上市股份（约占截至本公告日期1复宏汉霖股份总数2的3.87%），转让价 款共计港币517,444,099.80元（或等值人民币）。 本次增持完成后，本集团持有复宏汉霖的股权比例将增至63.43%（本次增持 前为59.56%）。 ●由于本公司执行董事关晓晖女士兼任无锡通善之间接控股股东Hermed Capital之董事，根据上证所《上市规则》，无锡通善构成本公司的关联方，本 次增持中，复星医药产业受让无锡通善持有之4,666,667股复宏汉霖非上市股份 构成本公司的关 ...

智通财经4月21日电，复星医药(600196.SH)公告称，4月11日至4月17日期间，本公司控股子公司复星医 药产业与上海善梧、无锡通善、舟山果运及Henlink分别签订转让协议，控股子公司复星医药产业拟以 港币24.60元/股的价格受让上海善梧、无锡通善、舟山果运及Henlink合计持有的2103万股复宏汉霖非上 市股份，转让价款共计港币5.17亿元。本次增持完成后，本集团持有复宏汉霖的股权比例将增至 63.43%。其中，复星医药产业受让无锡通善持有的4,666,667股复宏汉霖非上市股份构成本公司的关联 交易。本次增持不构成重大资产重组，无需提请董事会、股东会批准。 复星医药：拟以港币24.60元/股的价格受让2103万股复宏汉霖非上市股份 ...